Fund moves

Pfizer (PFE)Orbimed Advisors LLC exited its position 1.95M shares

Orbimed Advisors LLC exited its position in Pfizer, per its Q2 2026 13F.

1.95M
Prior-quarter shares · no longer reported
Holdings as of
Jun 30, 2026
Filed
Aug 14, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Nov 26, 2024CongressDisclosed sale of PFE — reported range $1,001 - $15,000
  2. Mar 10, 2025CongressDisclosed sale of PFE — reported range $15,001 - $50,000
  3. Mar 24, 2026CongressDisclosed sale of PFE — reported range $50,001 - $100,000
  4. Jun 8, 2026CongressDisclosed sale of PFE — reported range $15,001 - $50,000
  5. Jun 18, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On June 16, 2026, Dave Denton notified Pfizer Inc. (the “Company”) that he will step down from his current position as Chief Financial Officer effective August 15, 2026 for a professional opportunity outside of the pharmaceutical industry in consumer goods, and that his departure is not related to the Company’s financial or operating results or to any disagreements with the Company regarding the Company’s financial,…”
  6. Jun 24, 2026FDAFDA drug approval: Ibrance
  7. Jun 24, 2026FDAFDA drug approval: Ibrance
  8. Jul 6, 2026Government · Federal Register noticeEndo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
  9. Jul 20, 2026Government · Federal Register noticeForeign-Trade Zone (FTZ) 43, Notification of Proposed Production Activity; Pfizer Inc.; (Pharmaceutical Products); Kalamazoo and Portage, Michigan
  10. Aug 4, 2026Company filing · Form 8-K · ResultsReported its results
  11. Aug 5, 2026Insider · 3 peopleInsiders: 2 purchases (~$2.0M), 1 sale (~$83K)
  12. Aug 12, 2026Insider · Their first buy on recordCEO purchased ~$1M of PFE shares in the open market

What came next

  1. Aug 21, 2026Government · Federal Register noticeAdvisory Committee; Oncologic Drugs Advisory Committee; Renewal
  2. Sep 4, 2026FDARecall: Dopamine HCl Inj., USP, 200 mg/5 mL (40 mg/mL), 5 mL Single-dose, 25 vials per tray, Rx only, Distributed by Hospira, Inc., Lake Forest, IL 60045 USA, Vial NDC…
  3. Sep 25, 2026Government · Federal Register noticeJeffrey Thies: Final Debarment Order
  4. Oct 7, 2026FDAFDA drug approval: Tukysa
View the official recordSEC Form 13F-HR

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Pfizer

For Pfizer, OQRO holds 4 insider filings (SEC Form 4 or Form 144), 4 Congress trade reports and 54 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its PFE page.

How this filing works

Other disclosures at Pfizer

Everything OQRO holds on this company is on its PFE page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data